首页> 外文OA文献 >Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer

【2h】

Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer

机译：常规佐剂治疗后缺氧活化的前药Evofosfamide促进治疗结果，并在结直肠癌的临床前模型中靶向癌症引发细胞

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jennifer Haynes; Trevor D. McKee; Andrew Haller; Yadong Wang; Cherry Leung; Deena M.A. Gendoo; Evelyne Lima-Fernandes; Antonija Kreso; Robin Wolman; Eva Szentgyorgyi; Douglass C. Vines; Benjamin Haibe-Kains; Bradly G. Wouters; Ur Metser; David A. Jaffray; Myles Smith; Catherine A. OBrien;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer [J] . Haynes Jennifer, McKee Trevor D., Haller Andrew, Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第9期

机译：常规佐剂治疗后缺氧活化的前药Evofosfamide促进治疗结果，并在结直肠癌的临床前模型中靶向癌症引发细胞
2. Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models [J] . Jessica D Sun, Dharmendra Ahluwalia, Qian Liu, American Journal of Cancer Research . 2015,第7期

机译：缺氧激活前药evofosfamide（TH-302）和mTOR抑制剂的联合治疗可增强临床前肾细胞癌模型的抗肿瘤功效
3. Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models [J] . Jessica D Sun, Dharmendra Ahluwalia, Qian Liu, American Journal of Cancer Research . 2015,第7期

机译：缺氧激活前药evofosfamide（TH-302）和mTOR抑制剂的联合治疗可增强临床前肾细胞癌模型的抗肿瘤功效
4. The Role of Targeted Therapy in Adjuvant Colorectal Cancer Trials: Where Did We Go Wrong and Where Do We Go from Here? [C] . Alberto Sobrero, Marta Di Benedetto Gastrointestinal Cancers Symposium . 2012

机译：有针对性治疗在佐剂结直肠癌试验中的作用：我们在哪里出错，我们从这里去哪里？
5. Therapeutic Targeting of Chemotherapy-Resistant Colorectal Cancer Stem Cells with P73- and Trail-Based Small Molecules [D] . Prabhu, Varun Vijay. 2016

机译：基于P73和基于轨迹的小分子对化疗耐药的结直肠癌干细胞的治疗靶向
6. Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models [O] . Jessica D Sun, Dharmendra Ahluwalia, Qian Liu, 2015

机译：缺氧激活前药evofosfamide（TH-302）和mTOR抑制剂的联合治疗可增强临床前肾细胞癌模型的抗肿瘤功效
7. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models [O] . Jessica D. Sun, Qian Liu, Dharmendra Ahluwalia, 2016

机译：缺氧活化前药evofosfamide（Th-302）和IfOsfamide在临床前非小细胞肺癌模型的比较

Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅